FDA Determines Regulatory Review Period for IRESSA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Roche's cancer medication IRESSA, following a submission to the US Department of Commerce for patent extension, as required by law.